DOCS icon

Doximity

60.55 USD
-0.93
1.51%
At close Mar 27, 4:00 PM EDT
After hours
60.55
+0.00
0.00%
1 day
-1.51%
5 days
-1.59%
1 month
-12.81%
3 months
4.79%
6 months
41.14%
Year to date
13.05%
1 year
124.34%
5 years
14.25%
10 years
14.25%
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

258% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 33

40% more repeat investments, than reductions

Existing positions increased: 154 | Existing positions reduced: 110

24% more capital invested

Capital invested by funds: $4.98B [Q3] → $6.18B (+$1.21B) [Q4]

23% more funds holding

Funds holding: 348 [Q3] → 427 (+79) [Q4]

20% more call options, than puts

Call options by funds: $125M | Put options by funds: $104M

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

0.85% less ownership

Funds ownership: 91.26% [Q3] → 90.41% (-0.85%) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$55
9%
downside
Avg. target
$72
19%
upside
High target
$90
49%
upside

9 analyst ratings

positive
44%
neutral
56%
negative
0%
Mizuho
Steven Valiquette
50% 1-year accuracy
3 / 6 met price target
7%upside
$65
Neutral
Maintained
10 Feb 2025
Goldman Sachs
David Roman
30% 1-year accuracy
6 / 20 met price target
32%upside
$80
Neutral
Maintained
10 Feb 2025
Leerink Partners
Michael Cherny
68% 1-year accuracy
19 / 28 met price target
49%upside
$90
Outperform
Upgraded
7 Feb 2025
Canaccord Genuity
Richard Close
46% 1-year accuracy
13 / 28 met price target
17%upside
$71
Hold
Maintained
7 Feb 2025
Raymond James
Brian Peterson
31% 1-year accuracy
8 / 26 met price target
37%upside
$83
Outperform
Reiterated
7 Feb 2025

Financial journalist opinion

Based on 7 articles about DOCS published over the past 30 days

Positive
Zacks Investment Research
2 hours ago
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
Positive
Zacks Investment Research
5 days ago
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Doximity (DOCS) settling at $62.99, representing a +0.35% change from its previous close.
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
Positive
Investors Business Daily
1 week ago
Spotify, Rubrik Lead Five Growth Stocks Regaining This Key Level
Amid the market correction, few growth stocks are above their 50-day moving averages. Spotify, Rubrik lead five that have reclaimed that level.
Spotify, Rubrik Lead Five Growth Stocks Regaining This Key Level
Positive
Zacks Investment Research
2 weeks ago
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Positive
Zacks Investment Research
2 weeks ago
Buy 5 High-Flying Health & Fitness Stocks Year to Date With More Upside
Five Health & Fitness stocks have strong growth potential for 2025. These are: GRMN, SFM, DOCS, LTH, VFC.
Buy 5 High-Flying Health & Fitness Stocks Year to Date With More Upside
Positive
Zacks Investment Research
3 weeks ago
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Doximity (DOCS) possesses solid growth attributes, which could help it handily outperform the market.
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
4 weeks ago
5 Top-Ranked Stocks Poised for an Earnings Beat
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Lyft (LYFT), Garmin (GRMN) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
5 Top-Ranked Stocks Poised for an Earnings Beat
Neutral
MarketBeat
1 month ago
Market Shift: These 3 Stocks Are Winning While Big Tech Lags
As earnings season winds down, a notable trend has emerged in the markets: several mega-cap stocks have underperformed year-to-date (YTD). In contrast, several mid-to-large cap stocks with strong retail followings have delivered superior returns.
Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Neutral
Business Wire
1 month ago
DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or senior management failed to manage Doximity in an acceptable manner, in breach of their fiduciary dut.
DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS
Positive
Seeking Alpha
1 month ago
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
Charts implemented using Lightweight Charts™